Andersons pediatric cardiology 2356
Bạn đang xem bản rút gọn của tài liệu. Xem và tải ngay bản đầy đủ của tài liệu tại đây (77.16 KB, 3 trang )
Hematocrit,duringbypass,1399
Hemi-Fontanprocedure,1296–1297,1297f
Hemochromatosis,cardiacinvolvementin,1108–1109
Hemoconcentrators,incardiopulmonarybypass,227
Hemodilution,incardiopulmonarybypass,228
Hemodynamicassessment,inprematurity,192–195
bloodpressure,incirculatorystability,192,193f
hypotension,braininjuryand,192–194,194f
pretermcirculation,monitoring,194–195,195f
Hemodynamicinstability,incomplexcongenitalcardiacdisease,1399–1400
Hemodynamicvariables,indiagnosticcatheterization,240–242,241b
calculationsin,241–242
Hemodynamics
inEbsteinmalformation,596
echocardiographicmeasurementsand,305–306
meanpressuregradient,306,306f
duringpregnancy,1441
intetralogyofFallot,642–643
Heparin
forcardiaccatheterization,255
incardiopulmonarybypass,1289
inKawasakisyndrome,994–995
Hepatichemangioma,927–928
Hepaticveins,indiagnosticcatheterization,244
Hereditarymotorandsensoryneuropathy,cardiacinvolvementin,1106
Hersdisease,cardiacinvolvementin,1089
Heterotaxy,1419–1420
visceral,441
Highdependency,forintegratedcarepathways,1482t
High-fidelitycontinuousphysiologicdata,inFontanpathway,1275,1288–1289
High-resolutionepiscopicmicroscopy(HREM),88
High-riskclinic/follow-up,ininterstagemanagement,1313–1314
Histamine,incontrolofcirculation,1358
HLAsensitization,cardiactransplantationand,1226–1227
HLHS,Hypoplasticleftheartsyndrome
HMG-CoA,3-Hydroxy-3-methyl-glutarylcoenzymeA
Holt-Oramsyndrome,52–53,503,509,1416–1417,1416f,1416t
Homemonitoring,ininterstagemanagement,1311–1312,1313f–1314f
Homocystinuria
cardiacinvolvementin,1102
homozygous,systemicarterialdysfunctionand,1371
Homograft,220
Homograftvalves,222–223,222f
Homozygoushomocystinuria,systemicarterialdysfunctionand,1371
Hospitalization,psychologicalstressof,1455
Howell-Jollybodiesinisomericatrialappendages,454
HREM,High-resolutionepiscopicmicroscopy
Humanimmunodeficiencyvirus,inviralmyocarditis,1173
Humanleukocyteantigenalleles,associatedwithrheumaticfever,1001,1001t
Humanmyocardialdevelopment,61,62f
Humoralcontrol,ofcirculation,1357–1358
Huntersyndrome,cardiacinvolvementin,1090–1091
Hurlersyndrome,cardiacinvolvementin,1089–1090
Hurler-Scheiesyndrome,cardiacinvolvementin,1090
Hutchinson-Gilfordprogeria,cardiacinvolvementin,1112
HVAD,inlong-termmechanicalcirculatorysupport,1209–1210
Hybridcatheter/cardiacmagneticresonancelaboratory,328–329,329f
Hybridpalliation,1281
Hybridprocedure,1281,1282f,1284
ininterventionaltechniques,276–279,276f
combinedproceduresand,278–279,278f–279f
forhypoplasticleftheartsyndrome,276–277,277f
noveltreatmentsin,276–278
pulmonaryvalvereplacementand,278
forventricularseptalclosure,277–278,277f–278f
Hydralazine
forhypertension,1140t–1141t
forsystemichypertension,inprematureinfants,208f
3-Hydroxy-3-methyl-glutarylcoenzymeA(HMG-CoA),1436
11β−Hydroxylasedeficiency,hypertensionin,1136
17α−Hydroxylasedeficiency,hypertensionin,1136
Hypercalcemia,hypertensionin,1138
Hypercholesterolemia,familial,systemicarterialdysfunctionand,1371
Hypermetabolism,growthand,1495–1496
Hyper-reninism,primary,renalhypertensionand,1135
Hypersensitivitymyocarditis,drugsproducing,1111,1111b
Hypertension
cardiovascularriskfactors,426–428,427f–428f,427t–428t
followingcardiactransplantation,1238–1239
Hypertensivecrisis,medicaltherapyfor,1141–1142,1141t
Hyperthyroidism,cardiacinvolvementin,1096
Hypertriglyceridemia,pharmacologictherapyfor,433,434f
Hypertrophiccardiomyopathy,77,1145–1155,1146b
cardiopulmonaryexercisetestingin,1153
clinicalfeaturesof,1150–1153
clinicaloutcomesof,1145–1147
definitionof,1145
indiagnosticcatheterization,250
